Gland Pharma Limited (BOM:543245)

Market Cap	276.38B +14.9%
Revenue (ttm)	61.13B +6.7%
Net Income	8.47B +20.3%
EPS	51.42 +20.3%
Shares Out	n/a
PE Ratio	32.62
Forward PE	24.16
Dividend	18.00 (1.08%)
Ex-Dividend Date	Aug 14, 2025

Volume	3,740
Average Volume	5,934
Open	1,700.10
Previous Close	1,704.90
Day's Range	1,664.00 - 1,720.00
52-Week Range	1,200.00 - 2,130.00
Beta	n/a
RSI	35.57
Earnings Date	May 20, 2026

About Gland Pharma

Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neopla...

• Industry: Pharmaceutical Preparations
• Founded: 1978
• Employees: 4,351
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 543245

Financial Performance

In fiscal year 2025, Gland Pharma's revenue was 56.17 billion, a decrease of -0.85% compared to the previous year's 56.65 billion. Earnings were 6.99 billion, a decrease of -9.57%.